IP Library › Granted Patent US 10,100,109
Granted Patent B2
US 10,100,109 · App. 15/346,617 · Granted Oct 16, 2018

Anti-activin A antibodies and uses thereof

Inventors: Huiquan Han (Thousand Oaks, CA); Qing Chen (Oxnard, CA); Keith Soo-Nyung Kwak (Thousand Oaks, CA); Xiaolan Zhou (Newbury Park, CA)
Assignee: Amgen Inc.
C07K16/22A61K2039/505C07K2317/14C07K2317/21C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,100,109
App. No.
15/346,617
Granted
Oct 16, 2018
Kind
B2
Abstract

The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.

Claims (12)

1. An isolated anti-human activin A antibody or antigen binding fragment thereof, comprising:

a. a light chain variable domain (VL) comprising:

i. a light chain CDR1 sequence of SEQ ID NO:43;

ii. a light chain CDR2 sequence of SEQ ID NO:44; and

iii. a light chain CDR3 sequence of SEQ ID NO:45; and

b. a heavy chain variable domain (VH) comprising:

i. a heavy chain CDR1 sequence of SEQ ID NO:46;

ii. a heavy chain CDR2 sequence of SEQ ID NO:47; and

iii. a heavy chain CDR3 sequence of SEQ ID NO:48.

2. An isolated anti-human activin A antibody or antigen binding fragment thereof, comprising:

(a) a variable light chain sequence comprising SEQ ID NO: 41 and

(b) a variable heavy chain sequence comprising SEQ ID NO: 42.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2018
From: HAN, HQ; CHEN, QING; KWAK, KEITH SOO-NYUNG; ZHOU, XIAOLAN
To: AMGEN INC.
Reel/Frame 046714/0026 →
Continuity (6)
Continuation 14260856 · Apr 24, 2014
Continuation 13550447 · Jul 16, 2012
Continuation 11851884 · Sep 7, 2007
Provisional Application 60956653 · Aug 17, 2007
Provisional Application 60843430 · Sep 8, 2006
Related Publication 20170073408A1 · Mar 16, 2017